LIVIVO - Search results -

Search results

Result 1 - 10 of total 148

Search options

Book ; Online ; E-Book: Radiobiology of glioblastoma

Pirtoli, Luigi / Gravina, Giovanni Luca / Giordano, Antonio

recent advances and related pathobiology

(Current clinical pathology)

2016

Author's details	Luigi Pirtoli ; Giovanni Luca Gravina ; Antonio Giordano ed
Series title	Current clinical pathology
Language	English
Size	XX, 305 S. : Ill., graph. Darst.
Publisher	Humana Press
Publishing place	Cham
Publishing country	Switzerland
Document type	Book ; Online ; E-Book
Note	Lizenzpflichtig
Remark	Zugriff für angemeldete ZB MED-Nutzerinnen und -Nutzer
HBZ-ID	HT019042096
ISBN	978-3-319-28305-0 ; 9783319283036 ; 3-319-28305-7 ; 3319283030
DOI	10.1007/978-3-319-28305-0
Database	ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

Full text online

Accessible to users with ZB MED library card

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾
- Full text online
- Order with fees

Article: A Pharmacological Investigation of Eph-Ephrin Antagonism in Prostate Cancer: UniPR1331 Efficacy Evidence.

Festuccia, Claudio / Corrado, Miriam / Rossetti, Alessandra / Castelli, Riccardo / Lodola, Alessio / Gravina, Giovanni Luca / Tognolini, Massimiliano / Giorgio, Carmine

Pharmaceuticals (Basel, Switzerland)

2023 Volume 16, Issue 10

Abstract: The Eph kinases are the largest receptor tyrosine kinases (RTKs) family in humans. PC3 human prostate adenocarcinoma cells are a well-established model for studying Eph-ephrin pharmacology as they naturally express a high level of EphA2, a promising ... ...

Abstract	The Eph kinases are the largest receptor tyrosine kinases (RTKs) family in humans. PC3 human prostate adenocarcinoma cells are a well-established model for studying Eph-ephrin pharmacology as they naturally express a high level of EphA2, a promising target for new cancer therapies. A pharmacological approach with agonists did not show significant efficacy on tumor growth in prostate orthotopic murine models, but reduced distal metastasis formation. In order to improve the comprehension of the pharmacological targeting of Eph receptors in prostate cancer, in the present work, we investigated the efficacy of Eph antagonism both in vitro and in vivo, using UniPR1331, a small orally bioavailable Eph-ephrin interaction inhibitor. UniPR1331 was able to inhibit PC3 cells' growth in vitro in a dose-dependent manner, affecting the cell cycle and inducing apoptosis. Moreover, UniPR1331 promoted the PC3 epithelial phenotype, downregulating epithelial mesenchymal transition (EMT) markers. As a consequence, UniPR1331 reduced in vitro PC3 migration, invasion, and vasculomimicry capabilities. The antitumor activity of UniPR1331 was confirmed in vivo when administered alone or in combination with cytotoxic drugs in PC3-xenograft mice. Our results demonstrated that Eph antagonism is a promising strategy for inhibiting prostate cancer growth, especially in combination with cytotoxic drugs.
Language	English
Publishing date	2023-10-13
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2193542-7
ISSN	1424-8247
ISSN	1424-8247
DOI	10.3390/ph16101452
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Editorial: New Therapeutic Approaches for the Treatment of Glioblastoma.

Festuccia, Claudio / Gravina, Giovanni Luca

Current cancer drug targets

2017 Volume 17, Issue 3, Page(s) 200–202

MeSH term(s)	Animals ; Biomarkers, Tumor/blood ; Biomarkers, Tumor/genetics ; Brain Neoplasms/blood ; Brain Neoplasms/genetics ; Brain Neoplasms/pathology ; Brain Neoplasms/therapy ; Genetic Predisposition to Disease ; Glioblastoma/blood ; Glioblastoma/genetics ; Glioblastoma/pathology ; Glioblastoma/therapy ; Humans ; Prognosis
Chemical Substances	Biomarkers, Tumor
Language	English
Publishing date	2017-03-20
Publishing country	Netherlands
Document type	Editorial ; Introductory Journal Article
ZDB-ID	2064824-8
ISSN	1873-5576 ; 1568-0096
ISSN (online)	1873-5576
ISSN	1568-0096
DOI	10.2174/156800961703170201201627
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5589: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Abscopal Effect on Bone Metastases from Solid Tumors: A Systematic Review and Retrospective Analysis of Challenge within a Challenge.

Tomaciello, Miriam / Conte, Miriam / Montinaro, Francesca Romana / Sabatini, Arianna / Cunicella, Giorgia / Di Giammarco, Federico / Tini, Paolo / Gravina, Giovanni Luca / Cortesi, Enrico / Minniti, Giuseppe / De Vincentis, Giuseppe / Frantellizzi, Viviana / Marampon, Francesco

Biomedicines

2023 Volume 11, Issue 4

Abstract: Background: Abscopal effect (AE) describes the ability of radiotherapy (RT) to induce immune-mediated responses in nonirradiated distant metastasis. Bone represents the third most frequent site of metastasis and an immunologically favorable environment ... ...

Abstract	Background: Abscopal effect (AE) describes the ability of radiotherapy (RT) to induce immune-mediated responses in nonirradiated distant metastasis. Bone represents the third most frequent site of metastasis and an immunologically favorable environment for the proliferation of cancer cells. We revised the literature, searching documented cases of AE involving bone metastases (BMs) and evaluated the incidence of AE involving BMs in patients requiring palliative RT on BMs or non-BMs treated at our department. Methods: Articles published in the PubMed/MEDLINE database were selected using the following search criteria: ((abscopal effect)) AND ((metastases)). Patients with BMs, who underwent performed bone scintigraphy before and at least 2-3 months after RT, were selected and screened between January 2015 and July 2022. AE was defined as an objective response according to the scan bone index for at least one nonirradiated metastasis at a distance > 10 cm from the irradiated lesion. The primary endpoint was the rate of AE on BMs. Results: Ten cases experiencing AE of BMs were identified from the literature and eight among our patients. Conclusions: The analysis performed here suggests the use of hypofractionated radiotherapy as the only triggering factor for AE of BMs through the activation of the immune response.
Language	English
Publishing date	2023-04-12
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2720867-9
ISSN	2227-9059
ISSN	2227-9059
DOI	10.3390/biomedicines11041157
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: CT-guided cryoablation for management of bone metastases: a single center experience and review of the literature.

Arrigoni, Francesco / Bianchi, Giampaolo / Formiconi, Francesco / Palumbo, Pierpaolo / Zugaro, Luigi / Gravina, Giovanni Luca / Barile, Antonio / Masciocchi, Carlo

La Radiologia medica

2021 Volume 127, Issue 2, Page(s) 199–205

Abstract: Thermal ablation techniques are procedures of growing interest for management of bone metastases. Among these, cryoablation is probably the most advanced. It allows treatment of large and irregular volumes of pathological tissue, real-time evaluation of ... ...

Abstract	Thermal ablation techniques are procedures of growing interest for management of bone metastases. Among these, cryoablation is probably the most advanced. It allows treatment of large and irregular volumes of pathological tissue, real-time evaluation of the area of ablation and appears less painful than heat-based ablative techniques like radiofrequency and microwaves. Literature shows the effectiveness of cryoablation in the management of bone metastases in terms of pain palliation, but also its employment with curative intent is recommended. We reviewed the outcomes of cryoablation procedures performed in our radiology department over the last seven years, confirming the results in terms of pain palliation and local control of disease. We retrospectively evaluated results of 28 procedures of cryoablation, of which 17 treated with palliative and 11 with curative intent. In a 3-month follow-up study, we recorded an overall reduction of pain (evaluated using a VAS 0-10 scale) between pre- and post-treatment. The mean values dropped from 6.9 (SD: ± 1.3) to 3.5 (SD ± 2.6) (p < 0.0001). In the group of patients treated for local tumor control (follow-up: 22.4 months), we recorded a stability and/or reduction in volume of the lesion in 10 out 11 patients. No major complications were recorded.
MeSH term(s)	Adult ; Aged ; Aged, 80 and over ; Bone Neoplasms/diagnostic imaging ; Bone Neoplasms/secondary ; Bone Neoplasms/surgery ; Cryosurgery/methods ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Radiography, Interventional/methods ; Retrospective Studies ; Tomography, X-Ray Computed/methods ; Treatment Outcome
Language	English
Publishing date	2021-12-10
Publishing country	Italy
Document type	Journal Article ; Review
ZDB-ID	205751-7
ISSN	1826-6983 ; 0033-8362
ISSN (online)	1826-6983
ISSN	0033-8362
DOI	10.1007/s11547-021-01437-6
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Ue I Zs.59: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Editorial: New Drug Targets for Treatment of Recurrent/Metastatic Prostate Cancer.

Festuccia, Claudio / Negri-Cesi, Paola / Gravina, Giovanni Luca

Current drug targets

2016 Volume 17, Issue 3, Page(s) 254–256

MeSH term(s)	Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Bone Neoplasms/drug therapy ; Bone Neoplasms/secondary ; Drug Design ; Drug Resistance, Neoplasm ; Drug Screening Assays, Antitumor ; Humans ; Male ; Neoplasm Recurrence, Local/drug therapy ; Prostatic Neoplasms/drug therapy ; Tumor Microenvironment/drug effects
Chemical Substances	Antineoplastic Agents
Language	English
Publishing date	2016-02-01
Publishing country	United Arab Emirates
Document type	Editorial ; Introductory Journal Article
ZDB-ID	2064859-5
ISSN	1873-5592 ; 1389-4501
ISSN (online)	1873-5592
ISSN	1389-4501
DOI	10.2174/138945011703160125124500
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5578: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: The Botanical Drug PBI-05204, a Supercritical CO

Colapietro, Alessandro / Yang, Peiying / Rossetti, Alessandra / Mancini, Andrea / Vitale, Flora / Chakraborty, Sharmistha / Martellucci, Stefano / Marampon, Francesco / Mattei, Vincenzo / Gravina, Giovanni Luca / Iorio, Roberto / Newman, Robert A / Festuccia, Claudio

Frontiers in pharmacology

2022 Volume 13, Page(s) 852941

Abstract: Glioblastoma multiforme (GBM) is the most common as well as one of the most malignant types of brain cancer. Despite progress in development of novel therapies for the treatment of GBM, it remains largely incurable with a poor prognosis and a very low ... ...

Abstract	Glioblastoma multiforme (GBM) is the most common as well as one of the most malignant types of brain cancer. Despite progress in development of novel therapies for the treatment of GBM, it remains largely incurable with a poor prognosis and a very low life expectancy. Recent studies have shown that oleandrin, a unique cardiac glycoside from
Language	English
Publishing date	2022-03-23
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2587355-6
ISSN	1663-9812
ISSN	1663-9812
DOI	10.3389/fphar.2022.852941
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Anticancer effects of ABTL0812, a clinical stage drug inducer of autophagy-mediated cancer cell death, in glioblastoma models.

Mancini, Andrea / Colapietro, Alessandro / Cristiano, Loredana / Rossetti, Alessandra / Mattei, Vincenzo / Gravina, Giovanni Luca / Perez-Montoyo, Héctor / Yeste-Velasco, Marc / Alfon, Jose / Domenech, Carles / Festuccia, Claudio

Frontiers in oncology

2022 Volume 12, Page(s) 943064

Abstract: Background: Glioblastoma multiforme (GBM) is the most malignant adult brain tumor. Current standard of care treatments have very limited efficacy, being the patients´ overall survival 14 months and the 2-year survival rate less than 10%. Therefore, the ... ...

Abstract	Background: Glioblastoma multiforme (GBM) is the most malignant adult brain tumor. Current standard of care treatments have very limited efficacy, being the patients´ overall survival 14 months and the 2-year survival rate less than 10%. Therefore, the treatment of GBM is an urgent unmet clinical need. Methods: The aim of this study was to investigate Results: We showed that ABTL0812 inhibits cell proliferation in a wide panel of GBM cell lines and patient-derived glioblastoma stem cells (GSCs) with half maximal inhibitory concentrations (IC50s) ranging from 15.2 µM to 46.9 µM. Additionally, ABTL0812 decreased GSCs neurosphere formation. GBM cells aggressiveness is associated with a trans-differentiation process towards a less differentiated phenotype known as proneural to mesenchymal transition (PMT). ABTL0812 was shown to revert PMT and induce cell differentiation to a less malignant phenotype in GBM cell lines and GSCs, and consequently reduced cell invasion. As previously shown in other cancer types, we demonstrated that the molecular mechanism of action of ABTL0812 in glioblastoma involves the inhibition of Akt/mTORC1 axis by overexpression of TRIB3, and the activation of endoplasmic reticulum (ER) stress/unfolded protein response (UPR). Both actions converge to induce autophagy-mediated cell death. ABTL0812 anticancer efficacy was studied Conclusions: Overall, the present study demonstrated the anticancer efficacy of ABTL0812 as single agent and in combination with the GBM standard of care treatments in models of glioblastoma and supports the clinical investigation of ABTL0812 as a potential novel therapy for this aggressive brain tumor type.
Language	English
Publishing date	2022-11-02
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2649216-7
ISSN	2234-943X
ISSN	2234-943X
DOI	10.3389/fonc.2022.943064
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Hypofractionated Radiotherapy in Intermediate-Risk Prostate Cancer Patients: Long-Term Results.

Valeriani, Maurizio / Di Staso, Mario / Facondo, Giuseppe / Vullo, Gianluca / De Sanctis, Vitaliana / Gravina, Giovanni Luca / di Genesio Pagliuca, Milena / Osti, Mattia Falchetto / Bonfili, Pierluigi

Journal of clinical medicine

2022 Volume 11, Issue 16

Abstract: Background: To evaluate outcomes in terms of survival and toxicity in a series of intermediate-risk prostate cancer (PCa) patients treated with hypofractionated radiotherapy (HyRT) + hormonal therapy (HT) with or without image guidance (IGRT) and to ... ...

Abstract	Background: To evaluate outcomes in terms of survival and toxicity in a series of intermediate-risk prostate cancer (PCa) patients treated with hypofractionated radiotherapy (HyRT) + hormonal therapy (HT) with or without image guidance (IGRT) and to investigate the impact of different variables. Methods: This is a multi-centric study. From January 2005 to December 2019, we treated 313 intermediate-risk PCa patients (T2b−T2c, Gleason score 7, or pre-treatment PSA 10 to 20 ng/mL) with HyRT. Patients received 54.75 Gy in 15 fractions in 5 weeks plus 9 months of neo-adjuvant, concomitant, and adjuvant HT with or without IGRT. Results: Median follow-up was 91.6 months (range 5.1−167.8 months). Median OS was not reached, and the 8- and 10-year OS was 81.9% and 72.4%, respectively. Median CSS was not reached, and the 8- and 10-year CSS was 97.9% and 94.5%, respectively. PSA at first follow-up <0.8 ng/mL was significantly related to better oncological outcomes (CSS, bRFS, LRFS, cPFS, and MFS) in both univariate and multivariate analysis. After Propensity Score matching, grade 2−3 acute and cumulative late GU (p = 0.153 and p = 0.581, respectively) and GI (p = 0.196 and p = 0.925, respectively) toxicity were not statistically different in patients treated with or without IGRT. Conclusions: HyRT is effective and safe regardless of the use of IGRT. PSA at first follow-up is an easily accessible prognostic factor that may help the clinicians to identify patients who require a treatment intensification.
Language	English
Publishing date	2022-08-16
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2662592-1
ISSN	2077-0383
ISSN	2077-0383
DOI	10.3390/jcm11164783
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: ATX-101, a Peptide Targeting PCNA, Has Antitumor Efficacy Alone or in Combination with Radiotherapy in Murine Models of Human Glioblastoma.

Gravina, Giovanni Luca / Colapietro, Alessandro / Mancini, Andrea / Rossetti, Alessandra / Martellucci, Stefano / Ventura, Luca / Di Franco, Martina / Marampon, Francesco / Mattei, Vincenzo / Biordi, Leda Assunta / Otterlei, Marit / Festuccia, Claudio

Cancers

2022 Volume 14, Issue 2

Abstract: Cell proliferation requires the orchestrated actions of a myriad of proteins regulating DNA replication, DNA repair and damage tolerance, and cell cycle. Proliferating cell nuclear antigen (PCNA) is a master regulator which interacts with multiple ... ...

Abstract	Cell proliferation requires the orchestrated actions of a myriad of proteins regulating DNA replication, DNA repair and damage tolerance, and cell cycle. Proliferating cell nuclear antigen (PCNA) is a master regulator which interacts with multiple proteins functioning in these processes, and this makes PCNA an attractive target in anticancer therapies. Here, we show that a cell-penetrating peptide containing the AlkB homolog 2 PCNA-interacting motif (APIM), ATX-101, has antitumor activity in a panel of human glioblastoma multiforme (GBM) cell lines and patient-derived glioma-initiating cells (GICs). Their sensitivity to ATX-101 was not related to cellular levels of PCNA, or p53, PTEN, or MGMT status. However, ATX-101 reduced Akt/mTOR and DNA-PKcs signaling, and a correlation between high Akt activation and sensitivity for ATX-101 was found. ATX-101 increased the levels of γH2AX, DNA fragmentation, and apoptosis when combined with radiotherapy (RT). In line with the in vitro results, ATX-101 strongly reduced tumor growth in two subcutaneous xenografts and two orthotopic GBM models, both as a single agent and in combination with RT. The ability of ATX-101 to sensitize cells to RT is promising for further development of this compound for use in GBM.
Language	English
Publishing date	2022-01-07
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2527080-1
ISSN	2072-6694
ISSN	2072-6694
DOI	10.3390/cancers14020289
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

Full text online

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito